Search results for "Phase i ii"

showing 5 items of 5 documents

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunothera…

2017

0301 basic medicineMessenger RNAbusiness.industrymedicine.medical_treatmentMelanomaHematologyFirst in humanImmunotherapymedicine.diseaseClinical trial03 medical and health sciences030104 developmental biology0302 clinical medicinePhase i iiOncologyAntigen030220 oncology & carcinogenesisCancer researchmedicinebusinessLipoplexAnnals of Oncology
researchProduct

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in C…

2021

Abstract Background: Adoptive cell immunotherapies for opportunistic virus in immunocompromised patients using haploidentical memory T cells have shown to be safe and effective. Since severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state we have proposed that a similar strategy could be proven to be efficient for COVID-19 patients. This is a study protocol of an open-label, multicenter, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of the administration of a single dose of allogenic SARS-CoV-2 specific memory CD45RA - T cells and Natural Killer (NK)…

704.Cellular Immunotherapies: Clinicalbusiness.industryImmunologyCell BiologyHematologymedicine.disease_causemedicine.diseaseBiochemistryPneumoniaPhase i iiMulti center studyImmunologymedicineDose escalationbusinessCoronavirusBlood
researchProduct

Results of a Phase I-II Pilot Study with Intravescical Gemcitabine in Superficial Bladder Cancer (Ta-T1)

2005

To study the ablative activity of intravescical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods Twenty-seven patients were treated with intravescical gemcitabine after transurethral resection, during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six gemcitabine instillations were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hr, was given at a dose of 500, 1000 and 2000 mg in groups of nine patients each. A complete response (CR) was defined as negative cutologycystoscopy and biopsy findings. Results…

medicine.medical_specialtybusiness.industry030232 urology & nephrologyUrologyGeneral Medicinemedicine.diseaseGemcitabine03 medical and health sciences0302 clinical medicinePhase i iiTransitional cell carcinomaTolerability030220 oncology & carcinogenesisAblative casemedicineSuperficial bladder cancerbusinessmedicine.drugUrologia Journal
researchProduct

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL…

2021

Cancer ResearchBortezomibbusiness.industryHematologyGeneral Medicinechemistry.chemical_compoundPhase i iiOncologychemistryIbrutinibCancer researchmedicineRefractory Mantle Cell Lymphomabusinessmedicine.drugHematological Oncology
researchProduct

P-81 phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22

2020

Oncologymedicine.medical_specialtyQuality of life (healthcare)Phase i iiOncologybusiness.industryInternal medicineMedicineHematologybusinessAnnals of Oncology
researchProduct